A coiled-coil masking domain for selective activation of therapeutic antibodies

Ror2 signaling regulates Golgi structure and transport through IFT20 for tumor invasiveness

(2017) Michiru Nishita et al.   Scientific Reports

Trastuzumab in the Treatment of Breast Cancer

(2016) Sofia Maximiano et al.   BIODRUGS

Preclinical studies of a Pro-antibody-drug conjugate designed to selectively target EGFR-overexpressing tumors with improved therapeutic efficacy

(2016) Yun Yang et al.   mAbs

Generation and characterization of a target-selectively activated antibody against epidermal growth factor receptor with enhanced anti-tumor potency

(2015) Yun Yang et al.   mAbs

Moving targets: Emerging roles for MMPs in cancer progression and metastasis

(2015) Gemma Shay et al.   MATRIX BIOLOGY

Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index

(2015) Robert P Lyon et al.   NATURE BIOTECHNOLOGY

A new prodrug form of Affibody molecules (pro-Affibody) is selectively activated by cancer-associated proteases

(2014) Lisa Sandersjöö et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Probody therapeutics for targeting antibodies to diseased tissue

(2014) Krishna R Polu et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

A Set of de Novo Designed Parallel Heterodimeric Coiled Coils with Quantified Dissociation Constants in the Micromolar to Sub-nanomolar Regime

(2013) Franziska Thomas et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Tumor-Specific Activation of an EGFR-Targeting Probody Enhances Therapeutic Index

(2013) L. R. Desnoyers et al.   Science Translational Medicine

Abstract 4630: Integrin αVα6 is expressed on multiple solid tumors and is a potential therapeutic target for auristatin-based antibody-drug conjugates

(2012) Maureen C. Ryan et al.   CANCER RESEARCH

Site-specific targeting of antibody activity in vivo mediated by disease-associated proteases

(2012) Oran Erster et al.   JOURNAL OF CONTROLLED RELEASE

Concordance of preclinical and clinical pharmacology and toxicology of therapeutic monoclonal antibodies and fusion proteins: cell surface targets

(2011) Peter J Bugelski et al.   BRITISH JOURNAL OF PHARMACOLOGY

Design and development of masked therapeutic antibodies to limit off-target effects: Application to anti-EGFR antibodies

(2011) Joshua M. Donaldson et al.   CANCER BIOLOGY & THERAPY

Matrix Metalloproteinases: Regulators of the Tumor Microenvironment

(2010) Kai Kessenbrock et al.   CELL

The safety and side effects of monoclonal antibodies

(2010) Trevor T. Hansel et al.   NATURE REVIEWS DRUG DISCOVERY

Potent antitumor activity of the anti-CD19 auristatin antibody drug conjugate hBU12-vcMMAE against rituximab-sensitive and -resistant lymphomas

(2009) H.-P. Gerber et al.   BLOOD

Proligands with protease-regulated binding activity identified from cell-displayed prodomain libraries

(2009) Jerry M. Thomas et al.   PROTEIN SCIENCE